(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property **Organization** International Bureau



(43) International Publication Date 14 October 2004 (14.10.2004)

(10) International Publication Number WO 2004/087143 A1

(51) International Patent Classification7: A61K 31/436,

A61P 31/04

(21) International Application Number:

PCT/EP2004/003510

2 April 2004 (02.04.2004) (22) International Filing Date:

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0307862.3

4 April 2003 (04.04.2003)

- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GRASSBERGER, Maximilian [AT/AT]; Schaumburgergasse 12/7, A-1040 Wien (AT). HILDEBRANDT, Johannes [DE/AT]; St. Laurentgasse 12, A-2512 Oeynhausen (AT). HIRSCH, Stefan [DE/DE]; Theodor-Heuss-Strasse 21A, 79539 Lörrach (DE). PAUL, Carle [FR/FR]; 20, rue du Sundgau, F-68100 Mulhouse (FR). RYDER, Neil, Stewart [GB/US]; 96 The Valley Road, Concord, MA 01742 (US). SEKKAT, Nabila [MA/CH]; Davidsbodenstrasse 34,

CH-4056 Basel (CH). STÜTZ, Anton [AT/AT]; Haymogasse 140, A-1238 Wien (AT).

- (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS COMPRISING MACROLIDE T-CELL IMMUNOMODULATORS OR IMMUNOSUPPRES-SANTS IN COMBINATION WITH ANTIBACTERIALS

(57) Abstract: Highly compatible or synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and an antibacterial such as sulfasalazin, ciprofloxacin, ofloxacin, erythromycin or gentamycin, optionally with a further pharmaceutically active agent, especially a retinoid, are provided, which are useful in particular in the treatment of diseases involving bacterial or suspected or anticipated bacterial infection, for immunomodulation or immunosuppression in conditions in which bacterial or suspected or anticipated bacterial colonisation of e.g. the skin plays a role, such as atopic, contact and seborrhoeic dermatitis, eczema, psoriasis, acne, rosacea, post-peel, skin burning, itching, or IBD, and in situations of bacterial resistance.

